Platinum compounds: A hope for future cancer chemotherapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 296-306

  Ali, Imran ^a   Wani, Waseem A ^a   Saleem, Kishwar ^a   Haque, Ashanul ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Chronology and future perspectives; Cis platin and its analogues; Comparison of chemotherapies; Mechanism of action; Recent developments; Therapeutic status

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOMEDAC; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; DOCETAXEL; EPTAPLATIN; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LOBAPLATIN; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; TRIPLATIN TETRANITRATE; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CYTOTOXICITY; DNA REPLICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPOKALEMIA; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUTH SQUAMOUS CELL CARCINOMA; NAUSEA AND VOMITING; NEOPLASM; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; STOMACH CANCER; TESTIS CANCER; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DISCOVERY; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 84873302114     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313020016     Document Type: Article

References (97)

1. Orvig, C.; Abrams, M.J. Medicinal inorganic chemistry: introduction. Chem. Rev., 1999, 99, 2201-2203.
2. Alderden, R.A.; Hall, M.D.; Hambley, T.W. The Discovery and development of cis-platin. J. Chem. Edu., 2006, 83, 728-734.
3. Kostova, I. Platinum Complexes as Anticancer Agents. Rec. Pat. Anti-Canc. Drug Disc., 2006, 1, 1-22.
4. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-699.
5. Bertini, I.; Gray, H.B.; Lippard, S.J.; Valentine, J.S. Bioinorganic Chemistry; University Science Books: Sausalito, California, 1994; pp. 523-590.
6. Kaim, W.; Schwederski, B. Bioinorganic chemistry: Inorganic element in the chemistry of life, Wiley: Stuttgart, 1993; pp. 363-384.
7. Grunicke, H.; Doppler, W.; Helliger, W.; Hermann, B.J.; Hofmann, J.; Lindner, H.; Puschendorf, B. Tumor biochemistry as basis for advances in tumor chemotherapy. Arch. Geschwulst. Forsch., 1986, 56, 193-201.
8. Zhukova, O.S.; Dobrynin, IaV. Current results and perspectives of the use of human tumor cell lines for antitumor drug screening. Vopr. Onkol., 2001, 47, 706-709.
9. Wang, Y.; Chiu, J.F. Proteomic Approaches in Understanding action mechanisms of metal-based anticancer drugs. Metal-Based Drugs, 2008, 1-9.
10. Burger, H.; Loos, W.J.; Eechoute, K.; Verweij, J.; Mathijssen, R.H.J.; Wiemer, E.A.C. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Res. Up., 2011, 14, 22-34.
11. Andrews, P.A.; Jones, J.A.; Varki, N.M.; Howell, S.B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun. 1990, 2, 93-100.
12. Ardizzoni, A.; Boni, L.; Tiseo, M.; Fossella, F.V.; Schiller, J.H.; Paesmans, M.; Radosavl-Jevic, D.; Paccagnella, A.; Zatloukal, P.; Mazzanti, P.; Bisset, D.; Rosell, R. Cis-platin versus carboplatin based chemotherapy in first line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst., 2007, 99, 847-857.
13. Blair, B.G.; Larson, C.A.; Safaei, R.; Howell, S.B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cis-platin and carboplatin. Clin. Cancer Res., 2009, 15, 4312-4321.
14. Borst, P.; Rottenberg, S.; Jonkers, J. How do real tumours become resistant to cis-platin? Cell Cycle, 2008, 7, 1353-1359.
15. Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Update, 2005, 8, 131-146.
16. Briz, O.; Serrano, M.A.; Rebollo, N.; Hagenbuch, B.; Meier, P.J.; Koepsell, H.; Marin, J.J. Carriers involved in targeting the cytostatic bile acid-cis-platin derivatives cis-diammine-chlorocholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol. Pharmacol., 2002, 61, 853-860.
17. Buchdunger, E.; Cioffi, C.L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B.J.; Lydon, N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 2000, 295, 139-145.
18. Abu-Surrah, A.S.; Kettunen, M. Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cis-platin. Curr. Med. Chem., 2006, 13, 1337-1357.
19. Rosenberg, B.; Van Camp, L.; Trosko, J.E.; Mansour, V.H. Platinum Compounds: a new class of potent antitumour agents. Nature, 1969, 222, 385-386.
20. Rosenberg, B. Platinum complexes for the treatment of cancer: Why the search goes on, in Chemistry and biochemistry of a leading anticancer drug. B. Lippert, Ed.; Wiley-VCH, New York, 1999; pp. 1-27.
21. Tinker, N.D.; Sharma, H.L., McAuliffe, C.A. In Platinum and Other Metal Complexes in Cancer Chemotherapy, M. Nicolini Ed.; Martinus Nijhoff: Boston, MA, 1988; pp 144-159.
22. Rosenberg, B.; Van Camp, L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res., 1970, 30, 1799-1802.
23. Kociba, R.; Sleiht, S.D.; Rosenberg, B. Inhibition of Dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother. Rep., 1970, 54, 325-328.
24. Weiss, R.B.; Christian, M.C. New cis-platin analogues in development: A review. Drugs, 1993, 46, 360-377.
25. Bruijnincx, P.C.A.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12, 197-206.
26. Neidle, S.; Ismail, I.M.; Sadler, P.J.J. The structure of the antitumor complex cis-(diammino)(l,l-cyclobutane-dicarboxylato)-Pt(II): X-ray and NMR studies. Inorg. Biochem., 1980, 13, 205-212.
27. Canovese, L.; Cattalini, L.; Chessa, G.; Tobe, M.L. Kinetics of the displacement of cyclobutane-1,1-dicarboxylate from diammine (cyclobutane-1,1-dicarboxylato)platinum(II) in aqueous solution. J. Chem. Soc., Dalton Trans., 1988, 2135-2140.
28. Frey, U.; Ranford, J.D.; Sadler, P.J. Ring-opening reactions of the anticancer drug carboplatin: NMR characterization of cis-[Pt(NH3)2(CBDCA-O)(5'-GMP-N7)] in solution. Inorg. Chem., 1993, 32, 1333-1340.
29. Jakupec, M.A.; Galanski, M.; Keppler, B.K. Tumor inhibiting platinum complexes- state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol., 2003, 146, 1-53.
30. Armand, J.P.; Bolgie, V.; Raymond, E.; Fizazi, K.; Faivre, S.; Ducreux, M. Oxaliplatin in colorectal cancer: an overview. Semin. Oncol., 2000, 27, 96-104.
31. Kelland, L. The Resurgence of Platinum-based Cancer Chemotherapy. Nat. Rev. Cancer, 2007, 7, 573-584.
32. Boulikas T.; Vougiouka, M. Cis-platin and platinum drugs at the molecular level. Oncol. Rep., 2003, 10, 1663-1682.
33. Martindale. The complete drug reference,; 35th ed.; S.C. Sweetman, Ed.; Pharmaceutical Press: London, 2007.
34. Lordick, F.; Luber, B.; Lorenzen, S.; Hegewisch-Becker, S.; Folprecht, G.; Woll, E.; Decker, T.; Endlicher, E.; Rothling, N.; Schuster, T.; Keller, G.; Fend, F.; Peschel, C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br. J. Can., 2010, 102, 500-505.
35. Zarate, R.; Rodriguez, J.; Bandres, E.; Patino-Garcia, A.; Ponz-Sarvise, M.; Viudez, A.; Ramirez, N.; Bitarte, N.; Chopitea A.; Gacia-Foncillas, J. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br. J. Can., 2010, 102, 987-994.
36. Kasparkova, J.; Vojtiskova, M.; Natile G.; Brabec, V. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem. Eur. J., 2008, 14, 1330-1341.
37. Cassidy, J.; Misset, J.L. Oxaliplatin-related side effects: characteristics and management. Semin. Oncol., 2002, 29,11-20.
38. Kuwahara, A.; Yamamori, M.; Nishiguchi, K.; Okuno, T.; Chayahara, N.; Miki, I.; Tamura, T.; Inokuma, T.; Takemoto, Y.; Nakamura, T.; Kataoka, K.; Sakaeda, T. Replacement of cis-platin with nedaplatin in a definitive 5-fluorouracil/cis-platin -based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int. J. Med. Sci., 2009, 6, 305-311.
39. Alberto, E.M.; Lucas, M.F.A.; Pavelka, M.; Russo, N. The second-generation anticancer drug nedaplatin: a theoretical investigation on the hydrolysis mechanism. J. Phys. Chem. B., 2009, 113, 14473-14479.
40. Kawai, Y.; Taniuchi, S.; Okahara, S.; Nakamura, M.; Gemba, M. Relationship between cis-platin or nedaplatin induced nephrotoxicity and renal accumulation. Biol. Pharm. Bull., 2005, 28, 1385-1388.
41. Boulikas, T.; Pantos, A.; Bellis, E.; Christofis, P. Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther., 2007, 5, 537-583.
42. Kodaira, T.; Nobukazu, F.; Tachibana H.; Hidano, S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Antican. Res., 2006, 26, 2265-2268.
43. Kurita, H.; Yamamato, E.; Nozaki, S.; Wada, S.; Furuta, I.; Miyata, M.; Kurashina, K. Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Can. Chemother. Pharmacol., 2010, 65, 503-508.
44. Oshita, F.; Yamada, K.; Saito, H.; Noda, K.; Hamanaka N.; Ikehara, M. Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. J. Exp. Ther. Oncol., 2004, 4, 343-348.
45. A.I. Limited, Drugs R&D, 2003, 4, 369-372.
46. Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status o f platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans., 2010, 39, 8113-8127.
47. Shchepinov, M.S.; Denissenko, M.F.; Smylie, K.J.; Worl, R.J.; Leppin, A.L.; Cantor C.R.; Rodi, C.P. Matrix-induced fragmentation of P3 '-N5 ' phosphoramidate-containing DNA: high-throughput MALDI-TOF analysis of genomic sequence polymorphisms. Nucleic Acids Res., 2001, 29, 3864-3872.
48. Mross, K.; Meyberg, F.; Fieberg, H.H.; Hamm, K.; Hieber, U.; Aulenbacher, P.; Hossfeld, D.K. Pharmacokinetic and pharma-codynamic study with lobaplatin (D-19466), a new platinum complex, after bolus administration. Onkologie, 1992, 15, 139-146.
49. Gietema, J.A.; Guchelaar, H.J.; de Vries, E.G.E.; Alenbacher, P.; Seifer, D.Th.; Mulder, N.H. A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anti-Cancer Drugs, 1993, 4, 51-55.
50. Gietema, J.A.; Veldhuis, G.J.; Guchelaar, H.J.; Willemse, P.H.B.; Uges, D.R.A.; Cats, A.; Boonstra, H.; Van Der Graaf, W.T.A.; Sleijfer, D.T.; de Vries, E.G.E.; Mulder, N.H. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br. J. Cancer, 1995, 71, 1302-1307.
51. Kavanagh, J.J.; Edwards, C.L.; Freedman, R.S.; Finnegan, M.B.; Balat, O.; Tresukosol, D.; Bunk, K.; Loechner, S.; Hord, M.; Franklin J.L.; Kudelka, A.P. A trial of lobaplatin (D-19466) in platinum resistant ovarian cancer. Gynecol. Oncol., 1995, 58, 106-109.
52. Degardin, M.; Armand, J.P.; Chevallier, B.; Cappeleare, P.; Lentz, M.A.; David, M.; Roche, H. A clinical screening cooperative group phase II evaluation of lobaplatin ASTA D-19466) in advanced head and neck cancer. Invest. New Drugs, 1995, 13, 253-255.
53. Welink, J.; Boven, E.; Vermorken, J.B.; Gall H.E.; Vijgh, W.J.F.v.d. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Clin. Cancer Res., 1999, 5, 2349-2358.
54. Gietema, J.A.; de Vries, E.G.E.; Sleijfer, D.T.; Willemse, P.H.B.; Guchelaar, H.J.; Uges, D.R.A.; Aulenbacher, P.; Voegeli, R.; Mulder, N.H. A phase I study of 1, 2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br. J. Can., 1993, 67, 396-401.
55. Manegold, C.; Drings, P.; Gatzemeier, U.; Pawal, J.V.; Fiebig, H.H.; Queisser, W.; Edler, L. Lobaplatin (D-19466) in Patients with advanced non-small-cell lung cancer: a trial of the association for medical oncology (AIO) phase II study group. Onkologie, 1996, 19, 248-251.
56. Sternberg, C.N.; de Mulder, P.; Fossa, S.; Kaye, S.; Roberts, T.; Pawinsky, A.; Daamen, S. Lobaplatin in advanced urothelial tract tumors. Ann. Oncol., 1997, 8, 695-696.
57. Kim, D.K.; Kim, G.; Gam, J.; Cho, Y.B.; Kim, H.T.; Tai, J.H.; Kim, K.H.; Hong, W.S.; Park, J.G. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes. J. Med. Chem., 1994, 37, 1471-1485.
58. Kim, D.K.; Kim, H.T.; Tai, J.H.; Cho, Y.B.; Kim, T.S.; Kim, K.H.; Park J.G.; Hong, W.S. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother. Pharmacol., 1995, 37, 1-6.
59. Kim, D.K.; Kim, H.T.; Cho, Y.B.; Tai J.H.; Ahn, J.S.; Kim, T.S.; Kim, K.H. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother. Pharmacol., 1995, 35, 441-445.
60. Lee, J.W.; Park, J.K.; Lee, S.H.; Kim, S.Y.; Cho Y.B.; Kuh, H.J. Antitumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. Anti-Cancer Drugs, 2006, 17, 377-384.
61. Kim, N.K.; Kim, T.S.; Shin, S.G.; Park, Y.L.; Lee, J.A.; Cho, Y.B.; Kim, K.H.; Heo, D.S.; Bang, Y.J. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) in patients with advanced malignancies. Cancer, 2001, 91, 1549-1556.
62. Lee, W.S.; Lee, G.W.; Kim, H.W.; Lee, O.J.; Lee, Y.J.; Ko, G.H.; Lee, J.S.; Jang, J.S.; Ha, W.S. A phase II trial of heptaplatin/5-FU and leucovorin for advanced stomach cancer. Cancer Res. Treat., 2005, 37, 208-211.
63. Oh, S.C.; Yoon, S.Y.; Seo, J.H.; Choi, C.W.; Kim, B.Y.S.; Shin, S.G.; Kim, H.; Kim, S.Y.; Yoon, H.J.; Cho, K.S.; Kim, J.S. Pilot study of heptaplatin, UFT-E, and leucovorin in advanced gastric carcinoma. Cancer Res Treat., 2003, 35, 117-122.
64. Lee, K.H.; Hyun, M.S.; Kim, H.K.; Jin, H.M.; Yang, J.; Song, H.S.; Do, Y.R.; Ryoo, H.M.; Chung, J.S.; Zang, D.Y.; Lim, H.Y.; Jin, J.Y.; Yim, C.Y.; Park, H.S.; Kim, J.S.; Sohn, C.H.; Lee, S.N. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cis-platin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. Cancer Res. Treat., 2009, 41, 12-18.
65. Ohstu, A.; Shimada, Y.; Shirao, K.; Boku, N.; Hyodo, I.; Saito, H.; Yamamichi, N.; Miyata, Y.; Ikeda, N.; Yamamoto, S.; Fukuda, H.; Yoshida, S. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cis-platin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol., 2003, 21, 54-59.
66. Yamashita, H.; Nakagawa, H.; Tago, M.; Igaki, H.; Nakamura, N.; Shiraishi, M.; Sasano, N.; Ohtomo, K. Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cis-platin plus 5-fluorouracil regimen: a retrospective study. Dis. Esophagus., 2006, 19, 15-24.
67. Zheng, J.; Wang, G.; Yang, G.Y.; Wang, D.; Luo, X.; Chen, C.; Zhang, Z.; Li, Q.; Xu, W.; Li, Z. Wang, D. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Jpn. J. Clin. Oncol., 2010, 40, 425-431.
68. Kim, N.K.; Im, S.A.; Kim, D.K.; Lee, M.H.; Jung, C.W., Cho, E.K.; Lee, J.T.; Ahn, J.S.; Heo, D.S.; Bang, Y.J. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer, 1999, 86, 1109-1115.
69. Min, Y.J., Bang, S.J.; Shin, J.W.; Kim, D.H.; Park, J.H.; Kim, G.Y.; Ko, B.K.; Choi, D.H.; Cho, H.R. Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer. J. Korean Med. Sci., 2004, 19, 369-373.
70. Jamieson, E.R.; Lippard, S.J. Structure, recognition, and processing of cis-platin-DNA adducts. Chem. Rev., 1999, 99, 2467-2498.
71. Ishida, S.; Lee, J.; Thiele, D.J.; Herskowitz, I. Uptake of the anti-cancer drug cis-platin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci., 2002, 99, 14298-14302.
72. Lin, X.; Okuda, T.; Holzer, A.; Howell, S.B. The copper transporter CTR1 regulates cis-platin uptake in Saccharomyces cerevisiae. Mol. Pharmacol., 2002, 62, 1154-1159.
73. Kane, S.A.; Lippard, S.J. Photoreactivity of platinum(II) in cis-platin -modified DNA affords specific cross-links to HMG domain proteins. Biochem., 1996, 35, 2180-2188.
74. Cohen, S.M.; Lippard, S.J. Cis-platin: From DNA damage to cancer chemotherapy. Prog. Nuc. Acid Res. Mol. Biol., 2001, 67, 93-130.
75. Kartalou, M.; Essigmann, J.M. Recognition of cis-platin adducts by cellular proteins. Mutat. Res., 2001, 478, 1-21.
76. He, Q.; Liang, C.H.; Lippard S.J. Steroid hormones induce HMG1 over expression and sensitize breast cancer cells to cis-platin and carboplatin. Proc. Natl. Acad. Sci., 2000, 97, 5768-5772.
77. Zamble, D.B.; Mikata, Y.; Eng, C.H.; Sandman, K.E.; Lippard, S.J. Testis specific HMG-domain protein alters the responses of cells to cis-platin. J. Inorg. Biochem., 2002, 91, 451-462.
78. Wong, B.; Masse, J.E.; Yen, Y.M.; Giannikoupolous, P.; Feigon, J.; Johnson, R.C. Binding of cis-platin-modified DNA by Saccharomyces cerevisiae HMGB Protein Nhp6A. Biochem., 2002, 41, 5404-5414.
79. Wang, D.; Hara, R.; Singh, G.; Sancar, A.; Lippard, S.J. Nucleotide excision repair from a site-specifically platinum-modified nucleosomes. Biochem., 2003, 42, 6747-6753.
80. -). Anal. Biochem., 2000, 284, 77-86.
81. Mello, J.A.; Acharya, S.; Fishel, R.; Essigmann, J.M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cis-platin. Chem. Biol., 1996, 3, 579-589.
82. Brozovic, A.; Ambriović-Ristov, A.; Osmak, M. The relationship between cis-platin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cis-platin. Crit. Rev. Toxicol., 2010, 40, 347-359.
83. Florea, A.M.; Büsselberg, D. Cis-platin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers, 2011, 3, 1351-1371.
84. Gao, J.; Liu, Y.G.; Zingaro, R.A. Cytotoxic activities, cellular uptake, gene regulation, and optical imaging of novel platinum(II) complexes. Chem. Res. Toxicol., 2009, 22, 1705-1712.
85. Navarro, M.; Castro, W.; Higuera-Padilla, A.R.; Sierraalta, A.; Abad M.J.; Taylor, P.; Sánchez-Delgado R.A. Synthesis, characterization and biological activity of trans-platinum(II) complexes with chloroquine. J. Inorg. Biochem., 2011, 105, 1684-1691.
86. Banerjee, T.; Dubey, P.; Mukhopadhyay R. DNA compaction by mononuclear platinum cancer drug cis-platin and the trisplatinum anticancer agent BBR346 4: Differences and similarities. Biochimie., 2012, 94, 494-502.
87. Varbanov, H.; Valiahdi, S.M.; Legin, A.A.; Jakupec, M.A.; Roller, A., Galanski, M.; Keppler B.K. Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine) platinum(IV) complexes with higher cytotoxicity than cis-platin. Euro. J. Med. Chem., 2011, 46, 5456-5464.
88. Štarha, P.; Trávníček, Z.; Popa, I. Platinum (II)oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity. J. Inorg. Biochem., 2010, 104, 639-647.
89. Saha, P.; Descôteaux, C.; Brasseur, K.; Fortin, S.; Leblanc, V.; Parent, S.; Asselin, E.; Bérubé, G. Synthesis, antiproliferative activity and estrogen receptor a affinity of novel estradiol linked platinum (II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues. Euro. J. Med. Chem., 2012, 48, 385-390.
90. Galanski, M.; Keppler, B.K. Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anti-Cancer. Agents Med. Chem., 2007, 7, 55-73.
91. Ali, I.; Rahis-Uddin; Salim, K.; Rather, M.A.; Wani, W.A.; Haque, A. Advances in Nano Drugs for Cancer Chemotherapy. Curr. Can. Drug Tar., 2011, 11, 135-146.
92. Ali, I. Nano anti-cancer drugs: pros and cons and future perspectives. Curr. Can. Drug Tar., 2011, 11(2), 131-134.
93. Yang, K.; Chen, S.W.; Chen, R., Wan, Y.M. Experimental study of cis-platin loaded polylactic acid-polyethylene glycol nanoparticles for targeting oral carcinoma. Hua Xi Kou Qiang Yi Xue Za Zhi, 2005, 23, 445-448.
94. Peer, D.; Margalit, R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Can., 2004; 20, 780-789.
95. Mackay, F.S.; Sadler, P.J.; Bednarski, P.J. Photoactivatable platinum complexes. Anti-Cancer Agents Med. Chem., 2007, 7, 75-93.
96. Ott, I.; Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anti-Cancer Agents Med. Chem., 2007, 7, 95-110.
97. Ali, I.; Wani, W.A.; Saleem, K. Cancer scenario in India with future perspectives. Cancer Therapy, 2011, 8, 56-70.